Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01898832
Other study ID # zekai tahir burak- cholestasis
Secondary ID
Status Recruiting
Phase N/A
First received July 9, 2013
Last updated March 16, 2014
Start date July 2013
Est. completion date July 2014

Study information

Verified date July 2013
Source Zekai Tahir Burak Women's Health Research and Education Hospital
Contact ayse kirbas, md
Phone + 90 533 646 92 13
Email ayseozdemirkirbas@hotmail.com
Is FDA regulated No
Health authority Turkey: Ministry of Health
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of this study is to investigate maternal and fetal serum IL-17 levels in pregnant women with intrahepatic cholestasis of pregnancy and to find out if Th-17 cells have a role in progress of intrahepatic cholestasis of pregnancy.


Description:

Intrahepatic cholestasis of pregnancy (ICP) is the most prevalent pregnancy-specific liver disease. It occurs mainly in the second or third trimester of pregnancy. It typically resolves after delivery spontaneously but it is associated with an increased risk of adverse fetal outcomes.

The cause of ICP is heterogeneous, pathophysiology is poorly understood and therapies have been empiric. Genetic predispositions, environmental influences, dietary factors and hormonal influences have been studied and cited in the literature.

Comparing with placebo, ursodeoxycholic acid (UDCA) has been shown improvement in treatment of pruritus in previous studies. S-adenosylmethionine, guar gum, activated charcoal, dexamethasone, cholestyramine, etc. are not effective in the treatment of symptoms.

CD4+ T cells are an essential regulators of immune responses and inflammatory diseases. They are also called chief of orchestra cells of immune system. The balance between T helper-(Th)1, Th-2 and Th-17 cells and their cytokinergic interaction are crucial for the response of the organism. Th17 and its specific cytokine IL-17 are responsible for pathogenesis of autoimmune diseases as autoimmune uveitis, experimental autoimmune encephalomyelitis in animal models and potentially also in human autoimmune diseases such as multiple sclerosis, Crohn's disease, rheumatoid arthritis, psoriasis, primary biliary cirrhosis. Recently, IL-17 targeted therapies (secukinumab, ixekizumab and brodalumab) are being studied in Phase III clinical trials to evaluate their overall efficacy and safety for certain autoimmune diseases.

Th-17 levels have been investigated in normal and abnormal pregnancies and results were incompatible with each other. Some researchers have said that the level of IL-17 increased during pregnancy but the others not.

Low serum IL-17 is associated with premature birth. Up-regulation of the IL-17 is associated with preeclampsia.

K. Harada et all. (2009) demonstrated that IL-17-positive cells are associated with the chronic inflammation of bile ducts in primary biliary cirrhosis(PBC). Also, some authors demonstrated that Th-17-related cytokines were increased significantly in patients with PBC.

Maho Ichikawa et all. presented a case of male newborn infant who showed progressive severe cholestasis with selectively high Levels of Serum IL- 17.

Based on all this information, we decided to investigate maternal and fetal serum IL-17 levels of pregnants with ICP and the effects of UDCA therapy on it and find out if Th-17 cells have a role in progress of ICP.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date July 2014
Est. primary completion date June 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 39 Years
Eligibility Inclusion Criteria:

Clinical diagnosis of ICP

Exclusion Criteria:

multiple pregnancies known chronic illness

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Turkey Zekai Tahir Burak Ankara

Sponsors (1)

Lead Sponsor Collaborator
Zekai Tahir Burak Women's Health Research and Education Hospital

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary il-17 levels 12 months No
See also
  Status Clinical Trial Phase
Recruiting NCT05773677 - Diet in Twin Pregnancy: the Wellness of Mother and Babies. N/A
Completed NCT01499524 - The Metabolic Profile in Intrahepatic Cholestasis of Pregnancy and Diabetes Mellitus
Not yet recruiting NCT01226823 - Ursodeoxycholic Acid And Cholestasis Of Pregnancy Phase 3
Recruiting NCT03834285 - Liver Disease in Pregnancy
Recruiting NCT02480478 - Serum Autotaxin Levels in Cholestasis of Pregnancy N/A
Not yet recruiting NCT04890886 - Magnetic Resonance Imaging and Thermal Imaging of Adiposity in Neonates of Women With Metabolic Diseases
Recruiting NCT01906827 - P-wave Duration and Dispersion in Intrahepatic Cholestasis of Pregnancy N/A
Completed NCT00700232 - ABCB4 Gene Mutations in Intrahepatic Cholestasis of Pregnancy and Controls N/A
Terminated NCT04718961 - A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA) Phase 2
Completed NCT04922580 - Predictors of Adverse Neonatal Outcomes in Intrahepatic Cholestasis of Pregnancy
Recruiting NCT03519399 - Bile Acid Effects in Fetal Arrhythmia Study
Completed NCT05151913 - The Microbiome Composition in Women With Recurring Intrahepatic Cholestasis of Pregnancy (ICP)
Recruiting NCT05691036 - Bile Acids Metabolism and Genetic Mutation Profile in the ICP in the Indian Population
Withdrawn NCT01965054 - The Use of Fish Oil Supplementation in Treatment of Intrahepatic Cholestasis of Pregnancy N/A
Recruiting NCT05637151 - Different Effects of Delayed Clamping on Neonatal Bilirubin Levels Between Pregnant Women With Intrahepatic Cholestasis of Pregnancy and Normal Pregnant Women N/A
Not yet recruiting NCT06366659 - Unraveling the Pathogenesis of Pruritus in Intrahepatic Cholestasis of Pregnancy
Not yet recruiting NCT06364969 - Investigation of the Pruritogens of Liver-related Diseases